Welcome to our dedicated page for Taysha Gene Therapies SEC filings (Ticker: TSHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Taysha Gene Therapies, Inc. filings document regulatory disclosures for a Nasdaq-listed clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic CNS diseases. Its 8-K reports furnish financial results, business highlights, TSHA-102 clinical and regulatory updates, program-rights announcements, and exhibits tied to company press releases.
The filing record also includes proxy materials for annual stockholder meetings, director elections and voting matters, as well as material definitive agreement disclosures involving common-stock sales arrangements. Cover-page disclosures identify TSHA common stock, par value and Nasdaq listing status, while proxy filings provide formal governance and stockholder-meeting information.
A holder of TSHA common stock has filed a notice of proposed sale under Rule 144. The filing covers 30,052 shares of common stock to be sold through Maxim Group LLC on the Nasdaq, with an aggregate market value of $152,964.68. The filing notes that 273,919,373 shares of this class were outstanding at the time of the notice.
The shares to be sold were acquired on 01/23/2026 as a restricted stock unit (RSU) award from the issuer. The RSUs vested and were settled in stock on that date, with the consideration described as the reporting person’s continued service as an employee of the issuer. The signer also represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Taysha Gene Therapies (TSHA) has a planned sale of 54,916 shares of common stock under a Form 144 notice. The shares are to be sold through Maxim Group LLC on the Nasdaq, with an aggregate market value of 279,522.44 and an approximate sale date of 01/23/2026. The issuer reports 273,919,373 shares of this class outstanding.
The shares come from a restricted stock unit (RSU) award acquired on 01/23/2026, which vested and was settled in stock on the same date. The consideration for the grant was the reporting person’s continued service as an employee of the issuer.
An affiliate of the issuer has filed a notice of proposed sale of 32,077 shares of common stock under Rule 144. The planned sale, with an aggregate market value of $163,271.93, is to be executed through Maxim Group LLC on or about 01/23/2026 on the Nasdaq exchange.
The 32,077 shares were acquired on 01/23/2026 via an RSU award from the issuer, with payment in the form of the reporting person’s continued employment and the award vesting and settling in stock on that date. The filing notes that there were 273,919,373 shares of this class of common stock outstanding.
A TSHA security holder filed a notice of proposed sale under Rule 144 to sell 46,064 shares of common stock through broker Maxim Group LLC on or about 01/23/2026 on the Nasdaq market, with an indicated aggregate market value of $234,465.76. The filing notes that there were 273,919,373 shares of this class outstanding at the time of the notice. The seller acquired these shares on 01/23/2026 via a vested RSU award from the issuer, with the consideration described as the reporting person’s continued service as an employee.
An insider of TSHA has filed a notice of proposed sale under Rule 144 to sell up to 100,846 shares of common stock through broker Maxim Group LLC around 01/23/2026 on Nasdaq.
The shares were acquired on the same date via a vested RSU award from the issuer, with consideration described as the reporting person's continued service as an employee. The notice lists an aggregate market value of $513,306.14 for the planned sale and states that 273,919,373 common shares were outstanding.
BlackRock, Inc. has filed an amended Schedule 13G reporting a passive ownership stake in Taysha Gene Therapies Inc. BlackRock reports beneficial ownership of 17,852,291 shares of Taysha common stock, representing 6.5% of the class as of 12/31/2025. The firm reports sole power to vote 17,558,530 shares and sole power to dispose of 17,852,291 shares, with no shared voting or dispositive power.
The filing explains that these shares are held across certain BlackRock business units, and that various underlying persons have rights to dividends or sale proceeds, but no single person holds more than five percent of the total outstanding common shares. BlackRock certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Taysha Gene Therapies.
Taysha Gene Therapies, Inc. reported that its Chief Financial Officer, Kamran Alam, received new equity awards. On January 12, 2026 he was granted 359,000 shares of common stock in the form of restricted stock units, which will vest in four equal annual installments beginning on January 12, 2027, as long as he remains in continuous service.
On the same date, he also received an employee stock option to buy 231,000 shares of common stock at an exercise price of $4.86 per share, with 25% vesting on January 12, 2027 and the rest vesting in 36 equal monthly installments, subject to continued service. After these awards, he beneficially owned 1,546,603 shares of common stock directly and 231,000 stock options directly.
Taysha Gene Therapies, Inc. reported new equity awards to its Chief Executive Officer, Nolan Sean P. On January 12, 2026, he received 1,008,000 shares of common stock in the form of a restricted stock unit (RSU) award at a price of $0 per share, increasing his directly held common stock to 3,086,358 shares. The RSUs vest in four equal annual installments beginning on January 12, 2027, conditional on his continued service.
On the same date, he was granted an employee stock option for 648,000 shares of common stock with an exercise price of $4.86 per share, expiring on January 12, 2036. Twenty-five percent of the option vests on January 12, 2027, with the remainder vesting in 36 equal monthly installments thereafter, also subject to continued service. Separately, 1,535,545 shares of common stock are held indirectly through Nolan Capital, LLC, where he has shared voting and investment power.
Taysha Gene Therapies president and head of R&D Nagendran Sukumar reported multiple stock transactions on January 12, 2026. He exercised options for 111,324 shares of common stock at an exercise price of $0.6989 per share and 88,676 shares at $1.71 per share, then sold 200,000 shares of common stock at a weighted average price of $4.71 per share under a Rule 10b5-1 trading plan adopted on June 11, 2025.
After these moves, he directly held 1,006,439 shares of common stock before receiving an additional 427,000 restricted stock units, which increased his reported common stock holdings to 1,433,439 shares. He also received a new employee stock option for 274,000 shares at an exercise price of $4.86 per share, vesting over time starting January 12, 2027.
Taysha Gene Therapies insider Sukumar Nagendran has filed a Form 144 notice to sell 200,000 shares of common stock. The planned sale has an aggregate market value of $996,000, with trades expected around 01/12/2026 through Jefferies LLC on the Nasdaq market. The filing notes 273,920,000 shares of common stock outstanding.
The 200,000 shares were acquired via vested stock option grants from Taysha Gene Therapies, Inc. on 05/31/2023 (111,324 shares) and 01/02/2024 (88,676 shares. In the past three months, Nagendran has already sold 110,125 shares on 11/28/2025 for gross proceeds of $522,774.39 and 260,047 shares on 12/01/2025 for gross proceeds of $1,172,837.97.